Selection of zidovudine resistance mutations and escape of human immunodeficiency virus type 1 from antiretroviral pressure in stavudine-treated pediatric patients

Journal of Infectious Diseases

Volumn 185, Issue 8, 2002, Pages 1070-1076

  Maxeiner, Horst Guenter ^a,c   Keulen, Wilco ^a   Schuurman, Rob ^a   Bijen, Marc ^a   De Graaf, Loek ^a   Van Wijk, Albert ^a   Back, Nicole ^a   Kline, Mark W ^b   Boucher, Charles A B ^a   Nijhuis, Monique ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b TEXAS CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RNA DIRECTED DNA POLYMERASE; STAVUDINE;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; GENETIC RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; IN VITRO SELECTION; INFANT; MONOTHERAPY; NATURAL SELECTION; NONHUMAN; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; VIRUS LOAD; VIRUS MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; INFANT; MUTAGENESIS, SITE-DIRECTED; MUTATION; RNA, VIRAL; STAVUDINE; VIRAL LOAD; ZIDOVUDINE;

EID: 0037090053     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/339817     Document Type: Article

References (48)

1. Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription
2. 2′,3′-didehydro-2′,3′-dideoxythymidine (d4T), an anti HIV agent
3. Antiretroviral activity of stavudine (2′,3′-didehydro-3′-deoxythymidine, D4T)
4. Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine-experienced patients
5. Biologic effects and safety of stavudine: Overview of phase I and II clinical trials
6. Dose-related activity of stavudine in patients infected with human immunodeficiency virus
7. 2′3′-didehydro-3′-deoxythymidine (d4T) in patients with AIDS or AIDS-related complex: A phase I trial
8. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA, and immune complex-dissociated antigenemia
9. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection
10. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection
11. A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with HIV
12. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART
13. Immune reconstitution in HAART-treated children with AIDS
14. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA panel
15. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects
16. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT)
17. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine
18. Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene
19. Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2′,3′-didehydro-2′,3′-dideoxythymidine in cell culture
20. Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy
21. Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy
22. Stavudine resistance: An update on susceptibility following prolonged therapy
23. Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase
24. Clinical HIV-1 isolates remain sensitive to stavudine following prolonged therapy
25. A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multinucleoside inhibitors
26. Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multinucleoside analogs
27. Virological basis for HIV-1 resistance to stavudine investigated by analysis of clinical samples
28. Phenotypic and genotypic analysis of stavudine-resistant isolates of HIV
29. Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues
30. Genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 variants with insertions or deletions in the reverse transcriptase (RT): Multicenter study of patients treated with RT inhibitors
31. Rapid and simple PCR assay for quantification of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
32. Rapid and simple method for purification of nucleic acids
33. Lamivudine resistant HIV-1 variants (M184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo
34. A simple method of estimating fifty percent endpoints
35. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay
36. A novel phenotypic drug susceptibility assay for HIV-1
37. Effect of stavudine on human immunodeficiency virus type 1 virus load as measured by quantitative mononuclear cell culture, plasma RNA and immune complex-dissociated antigenemia
38. HIV-1 viral load, phenotype, and resistance in a subset of drug-naïve participants from the Deltra trial
39. Evolution of zidovudine resistance mutations in vivo can be explained by differences in viral fitness
40. Pol gene quasispecies of human immunodeficiency virus: Mutations associated with drug resistance in vires from patients undergoing no drug therapy
41. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates
42. Genotypic predictors of virologic response to stavudine after zidovudine monotherapy (ACTG302)
43. Development of zidovudine resistance in Jurkat T cells is associated with decreased expression of the thymidine kinase (TK) gene and hypermethylation of the 5′ end of human TK gene
44. Long-term exposure to zidovudine affects in vitro and in vivo the efficiency of phosphorylation of thymidine kinase
45. Anti-HIV antiviral activity of stavudine in a thymidine kinase-deficient cellular line
46. Mutational sensitivity patterns define critical residues in the palm subdomain of the reverse transcriptase of human immunodeficiency virus type 1
47. Nucleotide substitution patterns can predict the requirements for drug-resistance of HIV-1 proteins
48. Why does stavudine select zidovudine resistance mutations in vivo?